{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:57:50Z","timestamp":1790625470186,"version":"4.1.0"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,28]]},"DOI":"10.7759\/cureus.117095","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:16:16Z","timestamp":1790622976000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunomodulatory Properties of Mesenchymal Stem Cells and Their Extracellular Vesicles: Potential Clinical Applications in Autoimmune Diseases"],"prefix":"10.7759","author":[{"given":"Eduardo","family":"Ciarrochi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Bautista","family":"Ciarrochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03885-z","article-title":"Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities","volume":"15","author":"Zhidu S","year":"2024","unstructured":"Zhidu S, Ying T, Rui J, Chao Z. Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities. Stem Cell Res Ther. 2024, 15:266. 10.1186\/s13287-024-03885-z","journal-title":"Stem Cell Res Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger MF","year":"2019","unstructured":"Pittenger MF, Discher DE, P\u00e9ault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019, 4:22. 10.1038\/s41536-019-0083-6","journal-title":"NPJ Regen Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential","volume":"41","author":"Song N","year":"2020","unstructured":"Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020, 41:653-64. 10.1016\/j.tips.2020.06.009","journal-title":"Trends Pharmacol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231710023","article-title":"Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications","volume":"23","author":"Huang Y","year":"2022","unstructured":"Huang Y, Wu Q, Tam PK. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int J Mol Sci. 2022, 23:10023. 10.3390\/ijms231710023","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-018-0791-7","article-title":"Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine","volume":"9","author":"Keshtkar S","year":"2018","unstructured":"Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther. 2018, 9:63. 10.1186\/s13287-018-0791-7","journal-title":"Stem Cell Res Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-016-0363-7","article-title":"Mechanisms of mesenchymal stem\/stromal cell function","volume":"7","author":"Spees JL","year":"2016","unstructured":"Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem\/stromal cell function. Stem Cell Res Ther. 2016, 7:125. 10.1186\/s13287-016-0363-7","journal-title":"Stem Cell Res Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00932-0","article-title":"The secretion profile of mesenchymal stem cells and potential applications in treating human diseases","volume":"7","author":"Han Y","year":"2022","unstructured":"Han Y, Yang J, Fang J, et al.. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther. 2022, 7:92. 10.1038\/s41392-022-00932-0","journal-title":"Signal Transduct Target Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang L","year":"2015","unstructured":"Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015, 278:369-95. 10.1111\/joim.12395","journal-title":"J Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047140","article-title":"Global landscape of autoimmune diseases across different lifespan: a three-decade perspective","volume":"105","author":"Xiao XP","year":"2026","unstructured":"Xiao XP, Wu MY, Li Y, Hu X, Qin BY. Global landscape of autoimmune diseases across different lifespan: a three-decade perspective. Medicine (Baltimore). 2026, 105:e47140. 10.1097\/MD.0000000000047140","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102423","article-title":"Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race","volume":"19","author":"Roberts MH","year":"2020","unstructured":"Roberts MH, Erdei E. Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race. Autoimmun Rev. 2020, 19:102423. 10.1016\/j.autrev.2019.102423","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178722","article-title":"Estimation of prevalence of autoimmune diseases in the United States using electronic health record data","volume":"135","author":"Abend AH","year":"2024","unstructured":"Abend AH, He I, Bahroos N, et al.. Estimation of prevalence of autoimmune diseases in the United States using electronic health record data. J Clin Invest. 2024, 135:e178722. 10.1172\/JCI178722","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1871523014666150514102027","article-title":"An update on anti-inflammatory compounds: a review","volume":"14","author":"Dhingra AK","year":"2015","unstructured":"Dhingra AK, Chopra B, Dass R, Mittal SK. An update on anti-inflammatory compounds: a review. Antiinflamm Antiallergy Agents Med Chem. 2015, 14:81-97. 10.2174\/1871523014666150514102027","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184367","article-title":"Animal models of inflammation for screening of anti-inflammatory drugs: implications for the discovery and development of phytopharmaceuticals","volume":"20","author":"Patil KR","year":"2019","unstructured":"Patil KR, Mahajan UB, Unger BS, et al.. Animal models of inflammation for screening of anti-inflammatory drugs: implications for the discovery and development of phytopharmaceuticals. Int J Mol Sci. 2019, 20:4367. 10.3390\/ijms20184367","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2022.02.009","article-title":"The use of patient-specific stem cells in different autoimmune diseases","volume":"29","author":"Mohammedsaleh ZM","year":"2022","unstructured":"Mohammedsaleh ZM. The use of patient-specific stem cells in different autoimmune diseases. Saudi J Biol Sci. 2022, 29:3338-46. 10.1016\/j.sjbs.2022.02.009","journal-title":"Saudi J Biol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01037-x","article-title":"Challenges and advances in clinical applications of mesenchymal stromal cells","volume":"14","author":"Zhou T","year":"2021","unstructured":"Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, Lai P. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021, 14:24. 10.1186\/s13045-021-01037-x","journal-title":"J Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00149","article-title":"Mesenchymal stem cell-derived extracellular vesicles: challenges in clinical applications","volume":"8","author":"Gowen A","year":"2020","unstructured":"Gowen A, Shahjin F, Chand S, Odegaard KE, Yelamanchili SV. Mesenchymal stem cell-derived extracellular vesicles: challenges in clinical applications. Front Cell Dev Biol. 2020, 8:149. 10.3389\/fcell.2020.00149","journal-title":"Front Cell Dev Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao F","year":"2016","unstructured":"Gao F, Chiu SM, Motan DA, et al.. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016, 7:e2062. 10.1038\/cddis.2015.327","journal-title":"Cell Death Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1242\/dev.16.3.381","article-title":"Osteogenesis in transplants of bone marrow cells","volume":"16","author":"Friedenstein AJ","year":"1966","unstructured":"Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966, 16:381-90. 10.1242\/dev.16.3.381","journal-title":"J Embryol Exp Morphol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2184.1970.tb00347.x","article-title":"The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells","volume":"3","author":"Friedenstein AJ","year":"1970","unstructured":"Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970, 3:393-403. 10.1111\/j.1365-2184.1970.tb00347.x","journal-title":"Cell Tissue Kinet"},{"key":"ref20","article-title":"Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use","volume":"16","author":"Lazarus HM","year":"1995","unstructured":"Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995, 16:557-64.","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02313-9","article-title":"Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies","volume":"10","author":"Han X","year":"2025","unstructured":"Han X, Liao R, Li X, et al.. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduct Target Ther. 2025, 10:262. 10.1038\/s41392-025-02313-9","journal-title":"Signal Transduct Target Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/scrt214","article-title":"Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application","volume":"4","author":"M\u00e9nard C","year":"2013","unstructured":"M\u00e9nard C, Tarte K. Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther. 2013, 4:64. 10.1186\/scrt214","journal-title":"Stem Cell Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2015.2413","article-title":"Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue","volume":"37","author":"Heo JS","year":"2016","unstructured":"Heo JS, Choi Y, Kim HS, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016, 37:115-25. 10.3892\/ijmm.2015.2413","journal-title":"Int J Mol Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici M","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, et al.. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8:315-17. 10.1080\/14653240600855905","journal-title":"Cytotherapy"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.06.005","article-title":"Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases","volume":"27","author":"Davies LC","year":"2025","unstructured":"Davies LC, Biard L, Garc\u00eda-Olmo D, et al.. Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases. Cytotherapy. 2025, 27:1326-37. 10.1016\/j.jcyt.2025.06.005","journal-title":"Cytotherapy"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau J","year":"2016","unstructured":"Galipeau J, Krampera M, Barrett J, et al.. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016, 18:151-9. 10.1016\/j.jcyt.2015.11.008","journal-title":"Cytotherapy"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186224","article-title":"Potency assays and biomarkers for cell-based advanced therapy medicinal products","volume":"14","author":"Capelli C","year":"2023","unstructured":"Capelli C, Cuofano C, Pavoni C, et al.. Potency assays and biomarkers for cell-based advanced therapy medicinal products. Front Immunol. 2023, 14:1186224. 10.3389\/fimmu.2023.1186224","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01134-4","article-title":"Stem cell-based therapy for human diseases","volume":"7","author":"Hoang DM","year":"2022","unstructured":"Hoang DM, Pham PT, Bach TQ, et al.. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022, 7:272. 10.1038\/s41392-022-01134-4","journal-title":"Signal Transduct Target Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2011.06.008","article-title":"The MSC: an injury drugstore","volume":"9","author":"Caplan AI","year":"2011","unstructured":"Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011, 9:11-15. 10.1016\/j.stem.2011.06.008","journal-title":"Cell Stem Cell"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2478\/s11658-011-0019-7","article-title":"Perinatal sources of mesenchymal stem cells: Wharton's jelly, amnion and chorion","volume":"16","author":"Witkowska-Zimny M","year":"2011","unstructured":"Witkowska-Zimny M, Wrobel E. Perinatal sources of mesenchymal stem cells: Wharton's jelly, amnion and chorion. Cell Mol Biol Lett. 2011, 16:493-514. 10.2478\/s11658-011-0019-7","journal-title":"Cell Mol Biol Lett"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.76.56","article-title":"Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review","volume":"76","author":"Mizuno H","year":"2009","unstructured":"Mizuno H. Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J Nippon Med Sch. 2009, 76:56-66. 10.1272\/jnms.76.56","journal-title":"J Nippon Med Sch"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2016.09.012","article-title":"Comparative study of adipose-derived stem cells and bone marrow-derived stem cells in similar microenvironmental conditions","volume":"348","author":"Guneta V","year":"2016","unstructured":"Guneta V, Tan NS, Chan SK, Tanavde V, Lim TC, Wong TC, Choong C. Comparative study of adipose-derived stem cells and bone marrow-derived stem cells in similar microenvironmental conditions. Exp Cell Res. 2016, 348:155-64. 10.1016\/j.yexcr.2016.09.012","journal-title":"Exp Cell Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1159\/000448180","article-title":"Adipose tissue-derived stem cells in regenerative medicine","volume":"43","author":"Frese L","year":"2016","unstructured":"Frese L, Dijkman PE, Hoerstrup SP. Adipose tissue-derived stem cells in regenerative medicine. Transfus Med Hemother. 2016, 43:268-74. 10.1159\/000448180","journal-title":"Transfus Med Hemother"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-018-1008-9","article-title":"The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure","volume":"9","author":"He Y","year":"2018","unstructured":"He Y, Chen D, Yang L, Hou Q, Ma H, Xu X. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Res Ther. 2018, 9:263. 10.1186\/s13287-018-1008-9","journal-title":"Stem Cell Res Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23216","article-title":"The therapeutic potential of bone marrow-derived stromal cells","volume":"112","author":"Mezey E","year":"2011","unstructured":"Mezey E. The therapeutic potential of bone marrow-derived stromal cells. J Cell Biochem. 2011, 112:2683-7. 10.1002\/jcb.23216","journal-title":"J Cell Biochem"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01661-3","article-title":"A comparison of the use of adipose-derived and bone marrow-derived stem cells for peripheral nerve regeneration in vitro and in vivo","volume":"11","author":"Zhou LN","year":"2020","unstructured":"Zhou LN, Wang JC, Zilundu PL, et al.. A comparison of the use of adipose-derived and bone marrow-derived stem cells for peripheral nerve regeneration in vitro and in vivo. Stem Cell Res Ther. 2020, 11:153. 10.1186\/s13287-020-01661-3","journal-title":"Stem Cell Res Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.08.009","article-title":"Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells","volume":"17","author":"Watson N","year":"2015","unstructured":"Watson N, Divers R, Kedar R, Mehindru A, Mehindru A, Borlongan MC, Borlongan CV. Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. Cytotherapy. 2015, 17:18-24. 10.1016\/j.jcyt.2014.08.009","journal-title":"Cytotherapy"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127992","article-title":"Comparative characterization of cells from the various compartments of the human umbilical cord shows that the Wharton's jelly compartment provides the best source of clinically utilizable mesenchymal stem cells","volume":"10","author":"Subramanian A","year":"2015","unstructured":"Subramanian A, Fong CY, Biswas A, Bongso A. Comparative characterization of cells from the various compartments of the human umbilical cord shows that the Wharton's jelly compartment provides the best source of clinically utilizable mesenchymal stem cells. PLoS One. 2015, 10:e0127992. 10.1371\/journal.pone.0127992","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.570179","article-title":"Biological characteristics of umbilical cord mesenchymal stem cells and its therapeutic potential for hematological disorders","volume":"9","author":"Shang Y","year":"2021","unstructured":"Shang Y, Guan H, Zhou F. Biological characteristics of umbilical cord mesenchymal stem cells and its therapeutic potential for hematological disorders. Front Cell Dev Biol. 2021, 9:570179. 10.3389\/fcell.2021.570179","journal-title":"Front Cell Dev Biol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-021-00698-y","article-title":"Allogeneic vs. autologous mesenchymal stem\/stromal cells in their medication practice","volume":"11","author":"Li C","year":"2021","unstructured":"Li C, Zhao H, Cheng L, Wang B. Allogeneic vs. autologous mesenchymal stem\/stromal cells in their medication practice. Cell Biosci. 2021, 11:187. 10.1186\/s13578-021-00698-y","journal-title":"Cell Biosci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00725-7","article-title":"Mesenchymal stem\/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications","volume":"28","author":"Zhuang WZ","year":"2021","unstructured":"Zhuang WZ, Lin YH, Su LJ, et al.. Mesenchymal stem\/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci. 2021, 28:28. 10.1186\/s12929-021-00725-7","journal-title":"J Biomed Sci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01626","article-title":"Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning?","volume":"8","author":"Lohan P","year":"2017","unstructured":"Lohan P, Treacy O, Griffin MD, Ritter T, Ryan AE. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning?. Front Immunol. 2017, 8:1626. 10.3389\/fimmu.2017.01626","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132991","article-title":"Alloreactive immune response associated to human mesenchymal stromal cells treatment: a systematic review","volume":"10","author":"Sanabria-de la Torre R","year":"2021","unstructured":"Sanabria-de la Torre R, Qui\u00f1ones-Vico MI, Fern\u00e1ndez-Gonz\u00e1lez A, S\u00e1nchez-D\u00edaz M, Montero-V\u00edlchez T, Sierra-S\u00e1nchez \u00c1, Arias-Santiago S. Alloreactive immune response associated to human mesenchymal stromal cells treatment: a systematic review. J Clin Med. 2021, 10:2991. 10.3390\/jcm10132991","journal-title":"J Clin Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2575","article-title":"Concise review: MSC-derived exosomes for cell-free therapy","volume":"35","author":"Phinney DG","year":"2017","unstructured":"Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017, 35:851-8. 10.1002\/stem.2575","journal-title":"Stem Cells"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25617","article-title":"Exosomes derived from mesenchymal stem cells modulate miR-126 to ameliorate hyperglycemia-induced retinal inflammation via targeting HMGB1","volume":"60","author":"Zhang W","year":"2019","unstructured":"Zhang W, Wang Y, Kong Y. Exosomes derived from mesenchymal stem cells modulate miR-126 to ameliorate hyperglycemia-induced retinal inflammation via targeting HMGB1. Invest Ophthalmol Vis Sci. 2019, 60:294-303. 10.1167\/iovs.18-25617","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.05.004","article-title":"Mesenchymal stem cell secretome for regenerative medicine: where do we stand?","volume":"70","author":"Trigo CM","year":"2025","unstructured":"Trigo CM, Rodrigues JS, Cam\u00f5es SP, Sol\u00e1 S, Miranda JP. Mesenchymal stem cell secretome for regenerative medicine: where do we stand?. J Adv Res. 2025, 70:103-24. 10.1016\/j.jare.2024.05.004","journal-title":"J Adv Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0023-5","article-title":"Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases","volume":"14","author":"Shi Y","year":"2018","unstructured":"Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, Wang Y. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018, 14:493-507. 10.1038\/s41581-018-0023-5","journal-title":"Nat Rev Nephrol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2017.07.012","article-title":"Proteomic analysis of the secretome of human bone marrow-derived mesenchymal stem cells primed by pro-inflammatory cytokines","volume":"166","author":"Maffioli E","year":"2017","unstructured":"Maffioli E, Nonnis S, Angioni R, et al.. Proteomic analysis of the secretome of human bone marrow-derived mesenchymal stem cells primed by pro-inflammatory cytokines. J Proteomics. 2017, 166:115-26. 10.1016\/j.jprot.2017.07.012","journal-title":"J Proteomics"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches","volume":"13","author":"Welsh JA","year":"2024","unstructured":"Welsh JA, Goberdhan DC, O'Driscoll L, et al.. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024, 13:e12404. 10.1002\/jev2.12404","journal-title":"J Extracell Vesicles"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01704-0","article-title":"Clinical applications of stem cell-derived exosomes","volume":"9","author":"Tan F","year":"2024","unstructured":"Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024, 9:17. 10.1038\/s41392-023-01704-0","journal-title":"Signal Transduct Target Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-019-01663-0","article-title":"The therapeutic potential of mesenchymal stem cell-derived exosomes in treatment of neurodegenerative diseases","volume":"56","author":"Gorabi AM","year":"2019","unstructured":"Gorabi AM, Kiaie N, Barreto GE, Read MI, Tafti HA, Sahebkar A. The therapeutic potential of mesenchymal stem cell-derived exosomes in treatment of neurodegenerative diseases. Mol Neurobiol. 2019, 56:8157-67. 10.1007\/s12035-019-01663-0","journal-title":"Mol Neurobiol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S355366","article-title":"Targeted therapy for inflammatory diseases with mesenchymal stem cells and their derived exosomes: from basic to clinics","volume":"17","author":"Wang S","year":"2022","unstructured":"Wang S, Lei B, Zhang E, et al.. Targeted therapy for inflammatory diseases with mesenchymal stem cells and their derived exosomes: from basic to clinics. Int J Nanomedicine. 2022, 17:1757-81. 10.2147\/IJN.S355366","journal-title":"Int J Nanomedicine"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2174\/1566523217666170412110724","article-title":"Mesenchymal stem cell-derived extracellular vesicles for renal repair","volume":"17","author":"Nargesi AA","year":"2017","unstructured":"Nargesi AA, Lerman LO, Eirin A. Mesenchymal stem cell-derived extracellular vesicles for renal repair. Curr Gene Ther. 2017, 17:29-42. 10.2174\/1566523217666170412110724","journal-title":"Curr Gene Ther"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2012.0395","article-title":"Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis","volume":"22","author":"Li T","year":"2013","unstructured":"Li T, Yan Y, Wang B, et al.. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013, 22:845-54. 10.1089\/scd.2012.0395","journal-title":"Stem Cells Dev"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.12.043","article-title":"Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection","volume":"182","author":"Yu B","year":"2015","unstructured":"Yu B, Kim HW, Gong M, et al.. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. Int J Cardiol. 2015, 182:349-60. 10.1016\/j.ijcard.2014.12.043","journal-title":"Int J Cardiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-015-0116-z","article-title":"Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species","volume":"6","author":"Baglio SR","year":"2015","unstructured":"Baglio SR, Rooijers K, Koppers-Lalic D, et al.. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther. 2015, 6:127. 10.1186\/s13287-015-0116-z","journal-title":"Stem Cell Res Ther"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1525380","article-title":"Recent advances in the role of mesenchymal stem cells as modulators in autoinflammatory diseases","volume":"15","author":"Chen B","year":"2024","unstructured":"Chen B, Chen Z, He M, Zhang L, Yang L, Wei L. Recent advances in the role of mesenchymal stem cells as modulators in autoinflammatory diseases. Front Immunol. 2024, 15:1525380. 10.3389\/fimmu.2024.1525380","journal-title":"Front Immunol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S527137","article-title":"Stem cell-derived exosomes: a comprehensive review of biomedical applications, challenges, and future directions","volume":"20","author":"Zhang J","year":"2025","unstructured":"Zhang J, Tian X, Li Y, et al.. Stem cell-derived exosomes: a comprehensive review of biomedical applications, challenges, and future directions. Int J Nanomedicine. 2025, 20:10857-905. 10.2147\/IJN.S527137","journal-title":"Int J Nanomedicine"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2007.01844.x","article-title":"Immunomodulation by mesenchymal stem cells and clinical experience","volume":"262","author":"Le Blanc K","year":"2007","unstructured":"Le Blanc K, Ringd\u00e9n O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007, 262:509-25. 10.1111\/j.1365-2796.2007.01844.x","journal-title":"J Intern Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13267","article-title":"Immunogenicity of mesenchymal stromal\/stem cells","volume":"97","author":"Chen W","year":"2023","unstructured":"Chen W, Lv L, Chen N, Cui E. Immunogenicity of mesenchymal stromal\/stem cells. Scand J Immunol. 2023, 97:e13267. 10.1111\/sji.13267","journal-title":"Scand J Immunol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2009.10.002","article-title":"Mechanisms involved in the therapeutic properties of mesenchymal stem cells","volume":"20","author":"Meirelles Lda S","year":"2009","unstructured":"Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009, 20:419-27. 10.1016\/j.cytogfr.2009.10.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2006-0548","article-title":"Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism","volume":"25","author":"Djouad F","year":"2007","unstructured":"Djouad F, Charbonnier LM, Bouffi C, et al.. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007, 25:2025-32. 10.1634\/stemcells.2006-0548","journal-title":"Stem Cells"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.07.010","article-title":"The role of secreted factors in stem cells-mediated immune regulation","volume":"326","author":"Lin L","year":"2018","unstructured":"Lin L, Du L. The role of secreted factors in stem cells-mediated immune regulation. Cell Immunol. 2018, 326:24-32. 10.1016\/j.cellimm.2017.07.010","journal-title":"Cell Immunol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052472","article-title":"The cross-talk between mesenchymal stem cells and immune cells in tissue repair and regeneration","volume":"22","author":"Harrell CR","year":"2021","unstructured":"Harrell CR, Djonov V, Volarevic V. The cross-talk between mesenchymal stem cells and immune cells in tissue repair and regeneration. Int J Mol Sci. 2021, 22:2472. 10.3390\/ijms22052472","journal-title":"Int J Mol Sci"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1661340","article-title":"The interplay between mesenchymal stem cells and the immune microenvironment in rotator cuff tendon-to-bone healing: current progress and future directions","volume":"16","author":"Li D","year":"2025","unstructured":"Li D, Zou Y, Zhao Y. The interplay between mesenchymal stem cells and the immune microenvironment in rotator cuff tendon-to-bone healing: current progress and future directions. Front Immunol. 2025, 16:1661340. 10.3389\/fimmu.2025.1661340","journal-title":"Front Immunol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3002","article-title":"Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications","volume":"15","author":"Wang Y","year":"2014","unstructured":"Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014, 15:1009-16. 10.1038\/ni.3002","journal-title":"Nat Immunol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2012.26","article-title":"Mesenchymal stem cells: a double-edged sword in regulating immune responses","volume":"19","author":"Li W","year":"2012","unstructured":"Li W, Ren G, Huang Y, et al.. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ. 2012, 19:1505-13. 10.1038\/cdd.2012.26","journal-title":"Cell Death Differ"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2007.11.014","article-title":"Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide","volume":"2","author":"Ren G","year":"2008","unstructured":"Ren G, Zhang L, Zhao X, et al.. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008, 2:141-50. 10.1016\/j.stem.2007.11.014","journal-title":"Cell Stem Cell"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1391872","article-title":"The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility: in vivo study in the horse","volume":"11","author":"Cequier A","year":"2024","unstructured":"Cequier A, V\u00e1zquez FJ, Vitoria A, et al.. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility: in vivo study in the horse. Front Vet Sci. 2024, 11:1391872. 10.3389\/fvets.2024.1391872","journal-title":"Front Vet Sci"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2022.10.001","article-title":"Reciprocal regulation of mesenchymal stem cells and immune responses","volume":"29","author":"Wang Y","year":"2022","unstructured":"Wang Y, Fang J, Liu B, Shao C, Shi Y. Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell. 2022, 29:1515-30. 10.1016\/j.stem.2022.10.001","journal-title":"Cell Stem Cell"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7761","article-title":"Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice","volume":"176","author":"Sudres M","year":"2006","unstructured":"Sudres M, Norol F, Trenado A, et al.. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol. 2006, 176:7761-7. 10.4049\/jimmunol.176.12.7761","journal-title":"J Immunol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1496","article-title":"Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy","volume":"106","author":"Zappia E","year":"2005","unstructured":"Zappia E, Casazza S, Pedemonte E, et al.. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005, 106:1755-61. 10.1182\/blood-2005-04-1496","journal-title":"Blood"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01191-4","article-title":"The role of MSCs and CAR-MSCs in cellular immunotherapy","volume":"21","author":"Yan L","year":"2023","unstructured":"Yan L, Li J, Zhang C. The role of MSCs and CAR-MSCs in cellular immunotherapy. Cell Commun Signal. 2023, 21:187. 10.1186\/s12964-023-01191-4","journal-title":"Cell Commun Signal"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun L","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023, 8:235. 10.1038\/s41392-023-01471-y","journal-title":"Signal Transduct Target Ther"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2013.158","article-title":"Immunobiology of mesenchymal stem cells","volume":"21","author":"Ma S","year":"2014","unstructured":"Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014, 21:216-25. 10.1038\/cdd.2013.158","journal-title":"Cell Death Differ"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2007-0554","article-title":"Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells","volume":"26","author":"Selmani Z","year":"2008","unstructured":"Selmani Z, Naji A, Zidi I, et al.. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008, 26:212-22. 10.1634\/stemcells.2007-0554","journal-title":"Stem Cells"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2011.01069.x","article-title":"Immunomodulatory properties of mesenchymal stem cells: cytokines and factors","volume":"67","author":"Soleymaninejadian E","year":"2012","unstructured":"Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012, 67:1-8. 10.1111\/j.1600-0897.2011.01069.x","journal-title":"Am J Reprod Immunol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051222","article-title":"Cytokines differently define the immunomodulation of mesenchymal stem cells from the periodontal ligament","volume":"9","author":"Behm C","year":"2020","unstructured":"Behm C, Blufstein A, Gahn J, Nemec M, Moritz A, Rausch-Fan X, Andrukhov O. Cytokines differently define the immunomodulation of mesenchymal stem cells from the periodontal ligament. Cells. 2020, 9:1222. 10.3390\/cells9051222","journal-title":"Cells"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-075481","article-title":"A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells","volume":"110","author":"Chabannes D","year":"2007","unstructured":"Chabannes D, Hill M, Merieau E, et al.. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood. 2007, 110:3691-4. 10.1182\/blood-2007-02-075481","journal-title":"Blood"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.06.011","article-title":"Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease","volume":"35","author":"Cao W","year":"2011","unstructured":"Cao W, Yang Y, Wang Z, et al.. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity. 2011, 35:273-84. 10.1016\/j.immuni.2011.06.011","journal-title":"Immunity"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425405","article-title":"Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway","volume":"35","author":"Augello A","year":"2005","unstructured":"Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005, 35:1482-90. 10.1002\/eji.200425405","journal-title":"Eur J Immunol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2010.02378.x","article-title":"Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation","volume":"71","author":"Sioud M","year":"2010","unstructured":"Sioud M, Mobergslien A, Boudabous A, Fl\u00f8isand Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol. 2010, 71:267-74. 10.1111\/j.1365-3083.2010.02378.x","journal-title":"Scand J Immunol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118218","article-title":"Adipose derived mesenchymal stem cell exosomes loaded with miR-10a promote the differentiation of Th17 and Treg from naive CD4(+) T cell","volume":"259","author":"Bolandi Z","year":"2020","unstructured":"Bolandi Z, Mokhberian N, Eftekhary M, Sharifi K, Soudi S, Ghanbarian H, Hashemi SM. Adipose derived mesenchymal stem cell exosomes loaded with miR-10a promote the differentiation of Th17 and Treg from naive CD4(+) T cell. Life Sci. 2020, 259:118218. 10.1016\/j.lfs.2020.118218","journal-title":"Life Sci"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-023-08247-1","article-title":"In vitro treatment of murine splenocytes with extracellular vesicles derived from mesenchymal stem cells altered the mRNA levels of the master regulator genes of T helper cell subsets","volume":"50","author":"Yeganeh A","year":"2023","unstructured":"Yeganeh A, Fathollahi A, Hashemi SM, Yeganeh F. In vitro treatment of murine splenocytes with extracellular vesicles derived from mesenchymal stem cells altered the mRNA levels of the master regulator genes of T helper cell subsets. Mol Biol Rep. 2023, 50:3309-16. 10.1007\/s11033-023-08247-1","journal-title":"Mol Biol Rep"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2025.5673","article-title":"Importance of B cells (Review)","volume":"57","author":"Liu Z","year":"2026","unstructured":"Liu Z, Dai H, Cui X, Liu Y, Dong Z. Importance of B cells (Review). Int J Mol Med. 2026, 57:2. 10.3892\/ijmm.2025.5673","journal-title":"Int J Mol Med"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2657","article-title":"Human mesenchymal stem cells modulate B-cell functions","volume":"107","author":"Corcione A","year":"2006","unstructured":"Corcione A, Benvenuto F, Ferretti E, et al.. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006, 107:367-72. 10.1182\/blood-2005-07-2657","journal-title":"Blood"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/art.27560","article-title":"Interferon-\u03b3-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus","volume":"62","author":"Schena F","year":"2010","unstructured":"Schena F, Gambini C, Gregorio A, et al.. Interferon-\u03b3-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 2010, 62:2776-86. 10.1002\/art.27560","journal-title":"Arthritis Rheum"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.7150\/thno.32260","article-title":"Human mesenchymal stem cell-treated regulatory CD23+CD43+ B cells alleviate intestinal inflammation","volume":"9","author":"Chen X","year":"2019","unstructured":"Chen X, Cai C, Xu D, et al.. Human mesenchymal stem cell-treated regulatory CD23+CD43+ B cells alleviate intestinal inflammation. Theranostics. 2019, 9:4633-47. 10.7150\/thno.32260","journal-title":"Theranostics"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1038\/srep24120","article-title":"Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions","volume":"6","author":"Di Trapani M","year":"2016","unstructured":"Di Trapani M, Bassi G, Midolo M, et al.. Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci Rep. 2016, 6:24120. 10.1038\/srep24120","journal-title":"Sci Rep"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03053","article-title":"Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes","volume":"9","author":"Khare D","year":"2018","unstructured":"Khare D, Or R, Resnick I, Barkatz C, Almogi-Hazan O, Avni B. Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes. Front Immunol. 2018, 9:3053. 10.3389\/fimmu.2018.03053","journal-title":"Front Immunol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka A","year":"2016","unstructured":"Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016, 16:112-23. 10.1038\/nri.2015.9","journal-title":"Nat Rev Immunol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2004-0359","article-title":"Interactions between human mesenchymal stem cells and natural killer cells","volume":"24","author":"Sotiropoulou PA","year":"2006","unstructured":"Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006, 24:74-85. 10.1634\/stemcells.2004-0359","journal-title":"Stem Cells"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074997","article-title":"Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2","volume":"111","author":"Spaggiari GM","year":"2008","unstructured":"Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008, 111:1327-33. 10.1182\/blood-2007-02-074997","journal-title":"Blood"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050467","article-title":"Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome","volume":"8","author":"Harrell CR","year":"2019","unstructured":"Harrell CR, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells. 2019, 8:467. 10.3390\/cells8050467","journal-title":"Cells"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03516-z","article-title":"ADSC secretome constrains NK cell activity by attenuating IL-2-mediated JAK-STAT and AKT signaling pathway via upregulation of CIS and DUSP4","volume":"14","author":"Ko E","year":"2023","unstructured":"Ko E, Yoon T, Lee Y, Kim J, Park YB. ADSC secretome constrains NK cell activity by attenuating IL-2-mediated JAK-STAT and AKT signaling pathway via upregulation of CIS and DUSP4. Stem Cell Res Ther. 2023, 14:329. 10.1186\/s13287-023-03516-z","journal-title":"Stem Cell Res Ther"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02124-y","article-title":"Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets","volume":"10","author":"Guan F","year":"2025","unstructured":"Guan F, Wang R, Yi Z, et al.. Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduct Target Ther. 2025, 10:93. 10.1038\/s41392-025-02124-y","journal-title":"Signal Transduct Target Ther"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1042\/CS20220531","article-title":"M1\/M2 macrophages and their overlaps - myth or reality?","volume":"137","author":"Strizova Z","year":"2023","unstructured":"Strizova Z, Benesova I, Bartolini R, Novysedlak R, Cecrdlova E, Foley LK, Striz I. M1\/M2 macrophages and their overlaps - myth or reality?. Clin Sci (Lond). 2023, 137:1067-93. 10.1042\/CS20220531","journal-title":"Clin Sci (Lond)"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225680","article-title":"The importance of HLA assessment in \"off-the-shelf\" allogeneic mesenchymal stem cells based-therapies","volume":"20","author":"Kot M","year":"2019","unstructured":"Kot M, Baj-Krzyworzeka M, Szatanek R, Musia\u0142-Wysocka A, Suda-Szczurek M, Majka M. The importance of HLA assessment in \"off-the-shelf\" allogeneic mesenchymal stem cells based-therapies. Int J Mol Sci. 2019, 20:5680. 10.3390\/ijms20225680","journal-title":"Int J Mol Sci"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1905","article-title":"Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production","volume":"15","author":"N\u00e9meth K","year":"2009","unstructured":"N\u00e9meth K, Leelahavanichkul A, Yuen PS, et al.. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009, 15:42-9. 10.1038\/nm.1905","journal-title":"Nat Med"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1038\/srep38308","article-title":"Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE(2)-dependent mechanism","volume":"6","author":"Vasandan AB","year":"2016","unstructured":"Vasandan AB, Jahnavi S, Shashank C, Prasad P, Kumar A, Prasanna SJ. Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE(2)-dependent mechanism. Sci Rep. 2016, 6:38308. 10.1038\/srep38308","journal-title":"Sci Rep"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.189","article-title":"Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation","volume":"20","author":"Fran\u00e7ois M","year":"2012","unstructured":"Fran\u00e7ois M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012, 20:187-95. 10.1038\/mt.2011.189","journal-title":"Mol Ther"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2254","article-title":"Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation","volume":"34","author":"Luz-Crawford P","year":"2016","unstructured":"Luz-Crawford P, Djouad F, Toupet K, et al.. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells. 2016, 34:483-92. 10.1002\/stem.2254","journal-title":"Stem Cells"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1240301","article-title":"CCR2 positive exosome released by mesenchymal stem cells suppresses macrophage functions and alleviates ischemia\/reperfusion-induced renal injury","volume":"2016","author":"Shen B","year":"2016","unstructured":"Shen B, Liu J, Zhang F, et al.. CCR2 positive exosome released by mesenchymal stem cells suppresses macrophage functions and alleviates ischemia\/reperfusion-induced renal injury. Stem Cells Int. 2016, 2016:1240301. 10.1155\/2016\/1240301","journal-title":"Stem Cells Int"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02778-x","article-title":"Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p\/Stat1 pathway","volume":"21","author":"Ning Y","year":"2023","unstructured":"Ning Y, Huang P, Chen G, et al.. Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p\/Stat1 pathway. BMC Med. 2023, 21:96. 10.1186\/s12916-023-02778-x","journal-title":"BMC Med"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.04.016","article-title":"Development and function of dendritic cell subsets","volume":"40","author":"Mildner A","year":"2014","unstructured":"Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. 2014, 40:642-56. 10.1016\/j.immuni.2014.04.016","journal-title":"Immunity"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2014.0509","article-title":"Mesenchymal stromal cell-like cells set the balance of stimulatory and inhibitory signals in monocyte-derived dendritic cells","volume":"24","author":"Bacskai I","year":"2015","unstructured":"Bacskai I, M\u00e1zl\u00f3 A, Kis-T\u00f3th K, et al.. Mesenchymal stromal cell-like cells set the balance of stimulatory and inhibitory signals in monocyte-derived dendritic cells. Stem Cells Dev. 2015, 24:1805-16. 10.1089\/scd.2014.0509","journal-title":"Stem Cells Dev"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2009.50.351","article-title":"Human umbilical cord blood-derived stromal cells suppress xenogeneic immune cell response in vitro","volume":"50","author":"Hao L","year":"2009","unstructured":"Hao L, Zhang C, Chen XH, et al.. Human umbilical cord blood-derived stromal cells suppress xenogeneic immune cell response in vitro. Croat Med J. 2009, 50:351-60. 10.3325\/cmj.2009.50.351","journal-title":"Croat Med J"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S488201","article-title":"Emerging role and mechanism of mesenchymal stem cells-derived extracellular vesicles in rheumatic disease","volume":"17","author":"Wang Z","year":"2024","unstructured":"Wang Z, Yang C, Yan S, et al.. Emerging role and mechanism of mesenchymal stem cells-derived extracellular vesicles in rheumatic disease. J Inflamm Res. 2024, 17:6827-46. 10.2147\/JIR.S488201","journal-title":"J Inflamm Res"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3808-0","article-title":"Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients","volume":"59","author":"Favaro E","year":"2016","unstructured":"Favaro E, Carpanetto A, Caorsi C, et al.. Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients. Diabetologia. 2016, 59:325-33. 10.1007\/s00125-015-3808-0","journal-title":"Diabetologia"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00737","article-title":"Editorial: Regulation of inflammation in chronic disease","volume":"10","author":"Zhong J","year":"2019","unstructured":"Zhong J, Shi G. Editorial: Regulation of inflammation in chronic disease. Front Immunol. 2019, 10:737. 10.3389\/fimmu.2019.00737","journal-title":"Front Immunol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00160","article-title":"Resolution of inflammation: what controls its onset?","volume":"7","author":"Sugimoto MA","year":"2016","unstructured":"Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of inflammation: what controls its onset?. Front Immunol. 2016, 7:160. 10.3389\/fimmu.2016.00160","journal-title":"Front Immunol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1434533","article-title":"Editorial: Inflammation and chronic disease","volume":"11","author":"Orlando FA","year":"2024","unstructured":"Orlando FA, Mainous AG 3rd. Editorial: Inflammation and chronic disease. Front Med (Lausanne). 2024, 11:1434533. 10.3389\/fmed.2024.1434533","journal-title":"Front Med (Lausanne)"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.4103\/regenmed.regenmed-d-25-00006","article-title":"Safety of intravenous mesenchymal stem cell therapy: a meta-analysis of randomized controlled trials","volume":"2","author":"Habiba UE","year":"2025","unstructured":"Habiba UE, Greene DL, Ahmad K, et al.. Safety of intravenous mesenchymal stem cell therapy: a meta-analysis of randomized controlled trials. Regener Med Rep. 2025, 2:83-99. 10.4103\/regenmed.regenmed-d-25-00006","journal-title":"Regener Med Rep"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-181","article-title":"Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells","volume":"9","author":"Ra JC","year":"2011","unstructured":"Ra JC, Kang SK, Shin IS, et al.. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med. 2011, 9:181. 10.1186\/1479-5876-9-181","journal-title":"J Transl Med"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3057624","article-title":"Mesenchymal stem cell-based immunomodulation: properties and clinical application","volume":"2018","author":"Wang M","year":"2018","unstructured":"Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int. 2018, 2018:3057624. 10.1155\/2018\/3057624","journal-title":"Stem Cells Int"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki M","year":"2024","unstructured":"Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024, 103:e37297. 10.1097\/MD.0000000000037297","journal-title":"Medicine (Baltimore)"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092489","article-title":"A comprehensive review on neuroimmunology: insights from multiple sclerosis to future therapeutic developments","volume":"11","author":"Eva L","year":"2023","unstructured":"Eva L, Ple\u0219 H, Covache-Busuioc RA, et al.. A comprehensive review on neuroimmunology: insights from multiple sclerosis to future therapeutic developments. Biomedicines. 2023, 11:2489. 10.3390\/biomedicines11092489","journal-title":"Biomedicines"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi I","year":"2017","unstructured":"Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017, 88:137-45. 10.1136\/jnnp-2016-313300","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196311","article-title":"Mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis","volume":"12","author":"Islam MA","year":"2023","unstructured":"Islam MA, Alam SS, Kundu S, Ahmed S, Sultana S, Patar A, Hossan T. Mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis. J Clin Med. 2023, 12:6311. 10.3390\/jcm12196311","journal-title":"J Clin Med"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1038\/srep41837","article-title":"Amelioration of experimental autoimmune encephalomyelitis through transplantation of placental derived mesenchymal stem cells","volume":"7","author":"Jiang H","year":"2017","unstructured":"Jiang H, Zhang Y, Tian K, Wang B, Han S. Amelioration of experimental autoimmune encephalomyelitis through transplantation of placental derived mesenchymal stem cells. Sci Rep. 2017, 7:41837. 10.1038\/srep41837","journal-title":"Sci Rep"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3109","article-title":"Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models","volume":"15","author":"Bai L","year":"2012","unstructured":"Bai L, Lennon DP, Caplan AI, et al.. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci. 2012, 15:862-70. 10.1038\/nn.3109","journal-title":"Nat Neurosci"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2015.01.005","article-title":"Murine adipose-derived mesenchymal stromal cell vesicles: in vitro clues for neuroprotective and neuroregenerative approaches","volume":"17","author":"Farinazzo A","year":"2015","unstructured":"Farinazzo A, Turano E, Marconi S, Bistaffa E, Bazzoli E, Bonetti B. Murine adipose-derived mesenchymal stromal cell vesicles: in vitro clues for neuroprotective and neuroregenerative approaches. Cytotherapy. 2015, 17:571-8. 10.1016\/j.jcyt.2015.01.005","journal-title":"Cytotherapy"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040571","article-title":"Insights into exosome transport through the blood-brain barrier and the potential therapeutical applications in brain diseases","volume":"16","author":"Abdelsalam M","year":"2023","unstructured":"Abdelsalam M, Ahmed M, Osaid Z, Hamoudi R, Harati R. Insights into exosome transport through the blood-brain barrier and the potential therapeutical applications in brain diseases. Pharmaceuticals (Basel). 2023, 16:571. 10.3390\/ph16040571","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86988","article-title":"Immunomodulatory role of mesenchymal stem cell therapy in multiple sclerosis: a systematic review","volume":"17","author":"Amin MN","year":"2025","unstructured":"Amin MN, Hashish R, Agha Tabari K, Swami SS, Kasagga A, Assefa AK, Yu AK. Immunomodulatory role of mesenchymal stem cell therapy in multiple sclerosis: a systematic review. Cureus. 2025, 17:e86988. 10.7759\/cureus.86988","journal-title":"Cureus"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9463314","article-title":"Efficacy and safety of mesenchymal stem cell transplantation in the treatment of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis): a systematic review and meta-analysis of randomized controlled trial","volume":"2022","author":"Zeng L","year":"2022","unstructured":"Zeng L, Yu G, Yang K, Xiang W, Li J, Chen H. Efficacy and safety of mesenchymal stem cell transplantation in the treatment of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis): a systematic review and meta-analysis of randomized controlled trial. Stem Cells Int. 2022, 2022:9463314. 10.1155\/2022\/9463314","journal-title":"Stem Cells Int"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8536785","article-title":"Autologous mesenchymal stem cell transplantation in multiple sclerosis: a meta-analysis","volume":"2019","author":"Zhou Y","year":"2019","unstructured":"Zhou Y, Zhang X, Xue H, Liu L, Zhu J, Jin T. Autologous mesenchymal stem cell transplantation in multiple sclerosis: a meta-analysis. Stem Cells Int. 2019, 2019:8536785. 10.1155\/2019\/8536785","journal-title":"Stem Cells Int"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62726-4","article-title":"Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Nawar AA","year":"2024","unstructured":"Nawar AA, Farid AM, Wally R, et al.. Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2024, 14:12545. 10.1038\/s41598-024-62726-4","journal-title":"Sci Rep"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04184-x","article-title":"Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Zeng L","year":"2025","unstructured":"Zeng L, Liu C, Wu Y, et al.. Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2025, 16:65. 10.1186\/s13287-025-04184-x","journal-title":"Stem Cell Res Ther"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study","volume":"11","author":"Connick P","year":"2012","unstructured":"Connick P, Kolappan M, Crawley C, et al.. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012, 11:150-6. 10.1016\/S1474-4422(11)70305-2","journal-title":"Lancet Neurol"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou P","year":"2020","unstructured":"Petrou P, Kassis I, Levin N, et al.. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020, 143:3574-88. 10.1093\/brain\/awaa333","journal-title":"Brain"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.05.011","article-title":"Epidemiology of type 1 diabetes","volume":"39","author":"Maahs DM","year":"2010","unstructured":"Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010, 39:481-97. 10.1016\/j.ecl.2010.05.011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.34172\/hpp.2020.18","article-title":"Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis","volume":"10","author":"Mobasseri M","year":"2020","unstructured":"Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020, 10:98-115. 10.34172\/hpp.2020.18","journal-title":"Health Promot Perspect"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16628","article-title":"The pathophysiology, presentation and classification of type 1 diabetes","volume":"27","author":"Aamodt KI","year":"2025","unstructured":"Aamodt KI, Powers AC. The pathophysiology, presentation and classification of type 1 diabetes. Diabetes Obes Metab. 2025, 27:15-27. 10.1111\/dom.16628","journal-title":"Diabetes Obes Metab"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03860.x","article-title":"Analysis of islet inflammation in human type 1 diabetes","volume":"155","author":"Willcox A","year":"2009","unstructured":"Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009, 155:173-81. 10.1111\/j.1365-2249.2008.03860.x","journal-title":"Clin Exp Immunol"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2026.102034","article-title":"The multifaceted role of B lymphocytes in type 1 diabetes","volume":"82","author":"Khalefa SA","year":"2026","unstructured":"Khalefa SA, Ben Nasr M, Usuelli V, Yerra P, Lunati ME, Fiorina P. The multifaceted role of B lymphocytes in type 1 diabetes. Semin Immunol. 2026, 82:102034. 10.1016\/j.smim.2026.102034","journal-title":"Semin Immunol"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v7.i3.556","article-title":"Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models","volume":"7","author":"Klinker MW","year":"2015","unstructured":"Klinker MW, Wei CH. Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models. World J Stem Cells. 2015, 7:556-67. 10.4252\/wjsc.v7.i3.556","journal-title":"World J Stem Cells"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0844","article-title":"Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes","volume":"61","author":"Bassi \u00caJ","year":"2012","unstructured":"Bassi \u00caJ, Moraes-Vieira PM, Moreira-S\u00e1 CS, et al.. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes. 2012, 61:2534-45. 10.2337\/db11-0844","journal-title":"Diabetes"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06659-w","article-title":"Exosomes derived from mesenchymal stem cells in diabetes and diabetic complications","volume":"15","author":"Jiao YR","year":"2024","unstructured":"Jiao YR, Chen KX, Tang X, Tang YL, Yang HL, Yin YL, Li CJ. Exosomes derived from mesenchymal stem cells in diabetes and diabetic complications. Cell Death Dis. 2024, 15:271. 10.1038\/s41419-024-06659-w","journal-title":"Cell Death Dis"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27337","article-title":"The role of mesenchymal stem cells in the treatment of type 1 diabetes","volume":"14","author":"Jayasinghe M","year":"2022","unstructured":"Jayasinghe M, Prathiraja O, Perera PB, et al.. The role of mesenchymal stem cells in the treatment of type 1 diabetes. Cureus. 2022, 14:e27337. 10.7759\/cureus.27337","journal-title":"Cureus"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01619-6","article-title":"Mesenchymal stem cell-based therapy for type 1 & 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Kashbour M","year":"2025","unstructured":"Kashbour M, Abdelmalik A, Yassin MN, et al.. Mesenchymal stem cell-based therapy for type 1 & 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025, 17:189. 10.1186\/s13098-025-01619-6","journal-title":"Diabetol Metab Syndr"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej12-0343","article-title":"Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus","volume":"60","author":"Hu J","year":"2013","unstructured":"Hu J, Yu X, Wang Z, et al.. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013, 60:347-57. 10.1507\/endocrj.ej12-0343","journal-title":"Endocr J"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.09.015","article-title":"Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up","volume":"24","author":"Wu Z","year":"2022","unstructured":"Wu Z, Xu X, Cai J, et al.. Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up. Cytotherapy. 2022, 24:421-7. 10.1016\/j.jcyt.2021.09.015","journal-title":"Cytotherapy"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0171","article-title":"Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion","volume":"39","author":"Cai J","year":"2016","unstructured":"Cai J, Wu Z, Xu X, et al.. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016, 39:149-57. 10.2337\/dc15-0171","journal-title":"Diabetes Care"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03636-0","article-title":"Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration","volume":"15","author":"Ghoneim MA","year":"2024","unstructured":"Ghoneim MA, Gabr MM, El-Halawani SM, Refaie AF. Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration. Stem Cell Res Ther. 2024, 15:23. 10.1186\/s13287-024-03636-0","journal-title":"Stem Cell Res Ther"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.631463","article-title":"Stem cell-based clinical trials for diabetes mellitus","volume":"12","author":"de Klerk E","year":"2021","unstructured":"de Klerk E, Hebrok M. Stem cell-based clinical trials for diabetes mellitus. Front Endocrinol (Lausanne). 2021, 12:631463. 10.3389\/fendo.2021.631463","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1380443","article-title":"Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes","volume":"15","author":"Habiba UE","year":"2024","unstructured":"Habiba UE, Khan N, Greene DL, Ahmad K, Shamim S, Umer A. Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes. Front Endocrinol (Lausanne). 2024, 15:1380443. 10.3389\/fendo.2024.1380443","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai X","year":"2025","unstructured":"Dai X, Fan Y, Zhao X. Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther. 2025, 10:102. 10.1038\/s41392-025-02168-0","journal-title":"Signal Transduct Target Ther"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.10.004","article-title":"The pathogenesis of systemic lupus erythematosus-an update","volume":"24","author":"Choi J","year":"2012","unstructured":"Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol. 2012, 24:651-7. 10.1016\/j.coi.2012.10.004","journal-title":"Curr Opin Immunol"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00391","article-title":"Altered Th17\/Treg ratio in peripheral blood of systemic lupus erythematosus but not primary antiphospholipid syndrome","volume":"10","author":"\u00c1lvarez-Rodr\u00edguez L","year":"2019","unstructured":"\u00c1lvarez-Rodr\u00edguez L, Mart\u00ednez-Taboada V, Calvo-Al\u00e9n J, Beares I, Villa I, L\u00f3pez-Hoyos M. Altered Th17\/Treg ratio in peripheral blood of systemic lupus erythematosus but not primary antiphospholipid syndrome. Front Immunol. 2019, 10:391. 10.3389\/fimmu.2019.00391","journal-title":"Front Immunol"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103213","article-title":"Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus","volume":"22","author":"Wang H","year":"2023","unstructured":"Wang H, Li C, Ren G, et al.. Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus. Autoimmun Rev. 2023, 22:103213. 10.1016\/j.autrev.2022.103213","journal-title":"Autoimmun Rev"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1538-9","article-title":"Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis","volume":"11","author":"Zhou T","year":"2020","unstructured":"Zhou T, Liao C, Li HY, Lin W, Lin S, Zhong H. Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis. Stem Cell Res Ther. 2020, 11:48. 10.1186\/s13287-019-1538-9","journal-title":"Stem Cell Res Ther"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1002\/stem.68","article-title":"Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans","volume":"27","author":"Sun L","year":"2009","unstructured":"Sun L, Akiyama K, Zhang H, et al.. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009, 27:1421-32. 10.1002\/stem.68","journal-title":"Stem Cells"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00526","article-title":"Therapeutic development of mesenchymal stem cells or their extracellular vesicles to inhibit autoimmune-mediated inflammatory processes in systemic lupus erythematosus","volume":"8","author":"Sharma J","year":"2017","unstructured":"Sharma J, Hampton JM, Valiente GR, et al.. Therapeutic development of mesenchymal stem cells or their extracellular vesicles to inhibit autoimmune-mediated inflammatory processes in systemic lupus erythematosus. Front Immunol. 2017, 8:526. 10.3389\/fimmu.2017.00526","journal-title":"Front Immunol"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.3727\/096368911X582769c","article-title":"Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience","volume":"22","author":"Wang D","year":"2013","unstructured":"Wang D, Zhang H, Liang J, et al.. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2013, 22:2267-77. 10.3727\/096368911X582769c","journal-title":"Cell Transplant"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6518508","article-title":"Clinical efficacy and safety of mesenchymal stem cells for systemic lupus erythematosus","volume":"2020","author":"Zhou T","year":"2020","unstructured":"Zhou T, Li HY, Liao C, Lin W, Lin S. Clinical efficacy and safety of mesenchymal stem cells for systemic lupus erythematosus. Stem Cells Int. 2020, 2020:6518508. 10.1155\/2020\/6518508","journal-title":"Stem Cells Int"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2021.103324","article-title":"Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial","volume":"70","author":"Ranjbar A","year":"2022","unstructured":"Ranjbar A, Hassanzadeh H, Jahandoust F, et al.. Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial. Curr Res Transl Med. 2022, 70:103324. 10.1016\/j.retram.2021.103324","journal-title":"Curr Res Transl Med"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.80","article-title":"Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE","volume":"6","author":"Liang J","year":"2010","unstructured":"Liang J, Gu F, Wang H, et al.. Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE. Nat Rev Rheumatol. 2010, 6:486-9. 10.1038\/nrrheum.2010.80","journal-title":"Nat Rev Rheumatol"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang D","year":"2014","unstructured":"Wang D, Li J, Zhang Y, et al.. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014, 16:R79. 10.1186\/ar4520","journal-title":"Arthritis Res Ther"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo Q","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018, 6:15. 10.1038\/s41413-018-0016-9","journal-title":"Bone Res"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer HU","year":"2020","unstructured":"Scherer HU, H\u00e4upl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020, 110:102400. 10.1016\/j.jaut.2019.102400","journal-title":"J Autoimmun"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-025-01180-1","article-title":"T cell dysregulation in rheumatoid arthritis: from genetic susceptibility to established disease","volume":"27","author":"Chin A","year":"2025","unstructured":"Chin A, Small A, Wong SW, Wechalekar MD. T cell dysregulation in rheumatoid arthritis: from genetic susceptibility to established disease. Curr Rheumatol Rep. 2025, 27:14. 10.1007\/s11926-025-01180-1","journal-title":"Curr Rheumatol Rep"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750753","article-title":"B cells in rheumatoid arthritis: pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu F","year":"2021","unstructured":"Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, Zhang L. B cells in rheumatoid arthritis: pathogenic mechanisms and treatment prospects. Front Immunol. 2021, 12:750753. 10.3389\/fimmu.2021.750753","journal-title":"Front Immunol"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1186\/s13317-020-00145-x","article-title":"Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe","volume":"12","author":"Mousavi MJ","year":"2021","unstructured":"Mousavi MJ, Karami J, Aslani S, et al.. Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe. Auto Immun Highlights. 2021, 12:3. 10.1186\/s13317-020-00145-x","journal-title":"Auto Immun Highlights"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1002\/art.37894","article-title":"Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation","volume":"65","author":"Chen M","year":"2013","unstructured":"Chen M, Su W, Lin X, et al.. Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation. Arthritis Rheum. 2013, 65:1181-93. 10.1002\/art.37894","journal-title":"Arthritis Rheum"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1186\/ar3187","article-title":"Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis","volume":"12","author":"Liu Y","year":"2010","unstructured":"Liu Y, Mu R, Wang S, et al.. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2010, 12:R210. 10.1186\/ar3187","journal-title":"Arthritis Res Ther"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S571417","article-title":"Mesenchymal stem cell therapy in osteoarthritis and rheumatoid arthritis: a systematic review of exosomal microRNAs","volume":"19","author":"Hejazian SS","year":"2025","unstructured":"Hejazian SS, Hejazian SM, Mostafavi Montazeri SS, Abediazar S, Zununi Vahed S, Barzegari A. Mesenchymal stem cell therapy in osteoarthritis and rheumatoid arthritis: a systematic review of exosomal microRNAs. Biologics. 2025, 19:747-85. 10.2147\/BTT.S571417","journal-title":"Biologics"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111592","article-title":"Mesenchymal stem cell-based therapy for rheumatoid arthritis","volume":"22","author":"Sarsenova M","year":"2021","unstructured":"Sarsenova M, Issabekova A, Abisheva S, Rutskaya-Moroshan K, Ogay V, Saparov A. Mesenchymal stem cell-based therapy for rheumatoid arthritis. Int J Mol Sci. 2021, 22:11592. 10.3390\/ijms222111592","journal-title":"Int J Mol Sci"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284828","article-title":"Safety and efficacy of mesenchymal stem cells therapy in the treatment of rheumatoid arthritis disease: a systematic review and meta-analysis of clinical trials","volume":"18","author":"Mesa LE","year":"2023","unstructured":"Mesa LE, L\u00f3pez JG, L\u00f3pez Quiceno L, Barrios Arroyave F, Halpert K, Camacho JC. Safety and efficacy of mesenchymal stem cells therapy in the treatment of rheumatoid arthritis disease: a systematic review and meta-analysis of clinical trials. PLoS One. 2023, 18:e0284828. 10.1371\/journal.pone.0284828","journal-title":"PLoS One"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2299729","article-title":"A comprehensive review on the role of mesenchymal stromal\/stem cells in the management of rheumatoid arthritis","volume":"20","author":"Pignatti E","year":"2024","unstructured":"Pignatti E, Maccaferri M, Pisciotta A, Carnevale G, Salvarani C. A comprehensive review on the role of mesenchymal stromal\/stem cells in the management of rheumatoid arthritis. Expert Rev Clin Immunol. 2024, 20:463-84. 10.1080\/1744666X.2023.2299729","journal-title":"Expert Rev Clin Immunol"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.12.009","article-title":"Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1\/2 clinical trial","volume":"20","author":"Shadmanfar S","year":"2018","unstructured":"Shadmanfar S, Labibzadeh N, Emadedin M, et al.. Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1\/2 clinical trial. Cytotherapy. 2018, 20:499-506. 10.1016\/j.jcyt.2017.12.009","journal-title":"Cytotherapy"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.056","article-title":"Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran","volume":"109","author":"Ghoryani M","year":"2019","unstructured":"Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Poursamimi J, Mohammadi M. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran. Biomed Pharmacother. 2019, 109:1834-40. 10.1016\/j.biopha.2018.11.056","journal-title":"Biomed Pharmacother"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.632717","article-title":"Therapeutic use of mesenchymal stromal cells: the need for inclusive characterization guidelines to accommodate all tissue sources and species","volume":"9","author":"Wright A","year":"2021","unstructured":"Wright A, Arthaud-Day ML, Weiss ML. Therapeutic use of mesenchymal stromal cells: the need for inclusive characterization guidelines to accommodate all tissue sources and species. Front Cell Dev Biol. 2021, 9:632717. 10.3389\/fcell.2021.632717","journal-title":"Front Cell Dev Biol"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00458","article-title":"Human mesenchymal stromal cell (MSC) characteristics vary among laboratories when manufactured from the same source material: a report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative","volume":"8","author":"Stroncek DF","year":"2020","unstructured":"Stroncek DF, Jin P, McKenna DH, et al.. Human mesenchymal stromal cell (MSC) characteristics vary among laboratories when manufactured from the same source material: a report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Front Cell Dev Biol. 2020, 8:458. 10.3389\/fcell.2020.00458","journal-title":"Front Cell Dev Biol"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.10.008","article-title":"Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics","volume":"27","author":"Renesme L","year":"2025","unstructured":"Renesme L, Cobey KD, Lalu MM, et al.. Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics. Cytotherapy. 2025, 27:146-68. 10.1016\/j.jcyt.2024.10.008","journal-title":"Cytotherapy"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.1097\/JCN.0b013e318197a6a5","article-title":"Introduction to stem cell therapy","volume":"24","author":"Biehl JK","year":"2009","unstructured":"Biehl JK, Russell B. Introduction to stem cell therapy. J Cardiovasc Nurs. 2009, 24:98-103. 10.1097\/JCN.0b013e318197a6a5","journal-title":"J Cardiovasc Nurs"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum JA","year":"2014","unstructured":"Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014, 32:252-60. 10.1038\/nbt.2816","journal-title":"Nat Biotechnol"},{"key":"ref177","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117537","article-title":"Unveiling the immunogenicity of allogeneic mesenchymal stromal cells: challenges and strategies for enhanced therapeutic efficacy","volume":"180","author":"Li Y","year":"2024","unstructured":"Li Y, Jin M, Guo D, et al.. Unveiling the immunogenicity of allogeneic mesenchymal stromal cells: challenges and strategies for enhanced therapeutic efficacy. Biomed Pharmacother. 2024, 180:117537. 10.1016\/j.biopha.2024.117537","journal-title":"Biomed Pharmacother"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1400347","article-title":"The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review","volume":"12","author":"\u010cesnik AB","year":"2024","unstructured":"\u010cesnik AB, \u0160vajger U. The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review. Front Cell Dev Biol. 2024, 12:1400347. 10.3389\/fcell.2024.1400347","journal-title":"Front Cell Dev Biol"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0426","article-title":"Marketing of unproven stem cell-based interventions: a call to action","volume":"9","author":"Sipp D","year":"2017","unstructured":"Sipp D, Caulfield T, Kaye J, et al.. Marketing of unproven stem cell-based interventions: a call to action. Sci Transl Med. 2017, 9:eaag0426. 10.1126\/scitranslmed.aag0426","journal-title":"Sci Transl Med"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01282-z","article-title":"Therapeutic potential of mesenchymal stem cell-derived exosomes for regenerative medicine applications","volume":"24","author":"Roszkowski S","year":"2024","unstructured":"Roszkowski S. Therapeutic potential of mesenchymal stem cell-derived exosomes for regenerative medicine applications. Clin Exp Med. 2024, 24:46. 10.1007\/s10238-023-01282-z","journal-title":"Clin Exp Med"},{"key":"ref181","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02596-z","article-title":"Applications, challenges and prospects of mesenchymal stem cell exosomes in regenerative medicine","volume":"12","author":"Rezabakhsh A","year":"2021","unstructured":"Rezabakhsh A, Sokullu E, Rahbarghazi R. Applications, challenges and prospects of mesenchymal stem cell exosomes in regenerative medicine. Stem Cell Res Ther. 2021, 12:521. 10.1186\/s13287-021-02596-z","journal-title":"Stem Cell Res Ther"},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.70220","article-title":"From lab to industry: advancing the translational potential of extracellular vesicles through the ISEV Translation, Regulation and Advocacy Committee (ISEV-TRA)","volume":"15","author":"Gurriaran-Rodriguez U","year":"2026","unstructured":"Gurriaran-Rodriguez U, Bussolati B, Gimona M, et al.. From lab to industry: advancing the translational potential of extracellular vesicles through the ISEV Translation, Regulation and Advocacy Committee (ISEV-TRA). J Extracell Vesicles. 2026, 15:e70220. 10.1002\/jev2.70220","journal-title":"J Extracell Vesicles"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17080990","article-title":"Navigating the global regulatory landscape for exosome-based therapeutics: challenges, strategies, and future directions","volume":"17","author":"Verma N","year":"2025","unstructured":"Verma N, Arora S. Navigating the global regulatory landscape for exosome-based therapeutics: challenges, strategies, and future directions. Pharmaceutics. 2025, 17:990. 10.3390\/pharmaceutics17080990","journal-title":"Pharmaceutics"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00759-7","article-title":"MISEV2023: shaping the future of EV research by enhancing rigour, reproducibility and transparency","volume":"31","author":"Samuels M","year":"2024","unstructured":"Samuels M, Giamas G. MISEV2023: shaping the future of EV research by enhancing rigour, reproducibility and transparency. Cancer Gene Ther. 2024, 31:649-51. 10.1038\/s41417-024-00759-7","journal-title":"Cancer Gene Ther"},{"key":"ref185","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0955-9","article-title":"Early cessation of a randomised study in acute graft versus host disease: upfront mesenchymal stromal cells with corticosteroids versus corticosteroids alone","volume":"55","author":"Purtill D","year":"2020","unstructured":"Purtill D, Cirillo M, Fogarty J, et al.. Early cessation of a randomised study in acute graft versus host disease: upfront mesenchymal stromal cells with corticosteroids versus corticosteroids alone. Bone Marrow Transplant. 2020, 55:2199-201. 10.1038\/s41409-020-0955-9","journal-title":"Bone Marrow Transplant"},{"key":"ref186","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002109","article-title":"Revolutionizing medicine: recent developments and future prospects in stem-cell therapy","volume":"110","author":"Hussen BM","year":"2024","unstructured":"Hussen BM, Taheri M, Yashooa RK, Abdullah GH, Abdullah SR, Kheder RK, Mustafa SA. Revolutionizing medicine: recent developments and future prospects in stem-cell therapy. Int J Surg. 2024, 110:8002-24. 10.1097\/JS9.0000000000002109","journal-title":"Int J Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/530816-immunomodulatory-properties-of-mesenchymal-stem-cells-and-their-extracellular-vesicles-potential-clinical-applications-in-autoimmune-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:16:19Z","timestamp":1790622979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/530816-immunomodulatory-properties-of-mesenchymal-stem-cells-and-their-extracellular-vesicles-potential-clinical-applications-in-autoimmune-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":186,"URL":"https:\/\/doi.org\/10.7759\/cureus.117095","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}